Labiotech.eu

News and Trends 1 Jun 2015

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

ASCO Annual Meeting keeps bringing positive results of European companies that cross the ocean to present their clinical trial outcomes. DNA Therapeutics, the French biopharma, presented the results of the first-in-man phase I/IIa trial of DT01 in patients with cutaneous metastatic melanoma. Cancer cells can easily repair themselves after damage incurred in their DNA from […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

Eisai receives Europe’s OK for its Thyroid Cancer treatment

Lenvatinib, Eisai’s treatment of thyroid cancer, has received the marketing authorization of the European Commission. The Japanese company is increasing its European presence with Lenvatinib, an orally administered molecular-targeted agent. Lenvatinib, commercially sold under the name Lenvima, is a designated orphan drug in Japan, the United States and in Europe for the treatment of people with […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

Private investors have finally backed Mapi Pharma’s project with €9.1M. Shavit Capital has led the Series A financing round to support the company’s clinical development plans. The cash raised is sufficient to advance the company’s lead product Glatiramer Acetate (GA) Depot to its Phase III. The Israeli company has a bitter record of failed NASDAQ […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 1 Jun 2015

CRISPR technology receives the Spanish ‘Nobel prize’

CRISPR continues to amass prizes and to consolidate itself as the biggest discovery of the century. Its discoverers received last Wednesday the Princess of Asturias Award of Technical and Scientific Research. Emmanuel Charpentier and Jennifer Doudna, who shared the prize, received €50k. The prize was established in 1980 and consists in a series of annual prizes […]

June 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 31 May 2015

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

The big pharma companies Eli Lilly and AstraZeneca will combine two of their cancer drugs to make the perfect cocktail against solid tumors. They have entered a clinical collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor (MEDI4736), in combination with Cyramza (ramucirumab), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. MEDI4736 is […]

May 31, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 31 May 2015

Who are the European Cancer Champions?

Cancer makes no difference… Children, elderly, healthy, disabled, black, white, etc… the disease randomly selects its targets. One of the biggest challenges of the Biotech industry today, is to lead groundbreaking innovations capable of treating cancer, which also encompass each individual’s biological specificity. So who are the leading champions? Recently, Thomson Reuters listed the 5 […]

May 31, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 29 May 2015

Hyglos has a Solution Against Resistant Hospital Germs

Germany-based Hyglos and scientists from the universities of Tübingen, Münster and Munich join forces to develop a phage-based active substance against the dreaded hospital pathogen Staphylococcus aureus. Their secret lies in a highly effective protein from bacteria-specific viruses, the so-called bacteriophages, capable of rapidly killing the bacteria, which frequently occur in the nose. Due to the specific action of this […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 29 May 2015

Pfizer to Control Cellectis in a €1.5 Billion Deal?

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers. According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 29 May 2015

Poxel is Looking towards Japan’s Lucrative Diabetes Market

Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate. Imeglimin has already completed phase 2 clinical trials in type 2 diabetes patients in the US and EU and is ready for Phase III. This […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 28 May 2015

Biotechs outperformed in the top 40 European Tech Companies

EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs (Small and Medium-size companies), announced the launch of Tech 40, a label recognizing innovative European SMEs. Tech 40 puts young tech companies listed on Euronext markets – in Amsterdam, Brussels, Lisbon or Paris – under the spotlight. Companies awarded with the Tech 40 are operating in […]

May 28, 2015 - 2 minutesmins - By Nicolas Sainte-Foie

News and Trends 28 May 2015

Deinove Reaches Critical Milestones and Gets Recognition in the US

May 2015 is a great month for Deinove! The French company focused on Deinococci bacteria for green chemistry. Deinove reached critical milestone achievements in its industrial collaboration with Avril and their scientists gained major recognition in the US. Deinove is definitely on the front of the stage! A few days ago, Emmanuel Petiot, CEO of Deinove, declared that “All Deinove teams are […]

May 28, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 27 May 2015

Berlin’s biotech ecosystem, a fast-growing European hotspot

The Bionnale 2015, a major networking event for biotech in Berlin, is taking place today. Talks about Berlin’s cluster gave me a good insight on what’s happening here. Don’t expect Berlin to be a groundbreaking place like Boston or San Diego. The German capital has more conventional assets, but they’re definitely building a solid ecosystem. With more […]

May 27, 2015 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

DNA Therapeutics presents positive results for its breakthrough Advanced Cancer Therapy

Eisai receives Europe’s OK for its Thyroid Cancer treatment

After two failed IPOs, Mapi Pharma raised €9 Million from private investors

CRISPR technology receives the Spanish ‘Nobel prize’

AstraZeneca and Eli Lilly Combine their Innovative Drugs for Cancer Treatment

Who are the European Cancer Champions?

Hyglos has a Solution Against Resistant Hospital Germs

Pfizer to Control Cellectis in a €1.5 Billion Deal?

Poxel is Looking towards Japan’s Lucrative Diabetes Market

Biotechs outperformed in the top 40 European Tech Companies

Deinove Reaches Critical Milestones and Gets Recognition in the US

Berlin’s biotech ecosystem, a fast-growing European hotspot

Subscribe to our newsletter to get the latest biotech news!